S. Dhesi, Michael P. Chu, G. Blevins, I. Paterson, L. Larratt, G. Oudit, Daniel Kim
2013.1.1Journal of Investigative Medicine High Impact Case Reports
tlooto Summary
A case of cyclophosphamide-induced cardiomyopathy requiring mechanical circulatory support is presented and the pathophysiology, clinical manifestations, and risk factors for this important clinical entity are described and early detection and management strategies are proposed.
Abstract
Cyclophosphamide is increasingly used to treat various types of cancers and autoimmune conditions. Higher doses of this drug may produce significant cardiac toxicity, including fatal hemorrhagic myocarditis. In this review, we present a case of cyclophosphamide-induced cardiomyopathy requiring mechanical circulatory support. We also describe the pathophysiology, clinical manifestations, and risk factors for this important clinical entity and propose early detection and management strategies.
Citation format
DHESI, S., et al. Cyclophosphamide-induced cardiomyopathy. Journal of Investigative Medicine High Impact Case Reports, 2013, 1.